Phibro Animal Health - PAHC Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $14.75
  • Forecasted Upside: -15.91%
  • Number of Analysts: 4
  • Breakdown:
  • 2 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$17.54
▲ +0.13 (0.75%)

This chart shows the closing price for PAHC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Phibro Animal Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PAHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PAHC

Analyst Price Target is $14.75
▼ -15.91% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Phibro Animal Health in the last 3 months. The average price target is $14.75, with a high forecast of $21.00 and a low forecast of $9.00. The average price target represents a -15.91% upside from the last price of $17.54.

This chart shows the closing price for PAHC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 4 contributing investment analysts is to reduce stock in Phibro Animal Health. This Reduce consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
1/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
4/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
7/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
9/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
12/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
3/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
5/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
6/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2024BarclaysBoost TargetUnderweight ➝ Underweight$10.00 ➝ $13.00Low
12/7/2023BNP ParibasInitiated CoverageUnderperform$9.00Low
11/9/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$17.00 ➝ $16.00Low
8/31/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$18.00 ➝ $17.00Low
8/29/2023Roth MkmReiterated RatingBuy ➝ Buy$21.00Low
2/9/2023Morgan StanleyLower TargetEqual Weight$20.00 ➝ $19.00Low
12/21/2022Roth CapitalInitiated CoverageBuy$18.00Low
11/10/2022Morgan StanleyLower TargetEqual Weight$21.00 ➝ $20.00Low
9/16/2022BarclaysLower TargetUnderweight$22.00 ➝ $17.00Low
8/26/2022Morgan StanleyLower TargetEqual Weight$23.00 ➝ $21.00Low
7/25/2022BarclaysDowngradeEqual Weight ➝ Underweight$22.00Low
1/10/2022BarclaysUpgradeUnderweight ➝ Equal Weight$23.00High
11/18/2021Morgan StanleyInitiated CoverageEqual Weight$23.00Low
7/7/2021BarclaysDowngradeEqual Weight ➝ Underweight$23.00High
5/13/2021Morgan StanleyBoost TargetUnderweight$19.00 ➝ $22.00Low
8/6/2020Morgan StanleyDowngradeEqual Weight ➝ Underweight$20.00High
5/8/2020Credit Suisse GroupLower TargetNeutral$25.00 ➝ $23.00Low
3/31/2020G.ResearchUpgradeHold ➝ BuyMedium
2/6/2020G.ResearchDowngradeBuy ➝ HoldLow
2/6/2020GabelliDowngradeBuy ➝ Hold$30.00Low
1/28/2020BarclaysUpgradeUnderweight ➝ Equal Weight$23.00High
9/5/2019Morgan StanleyUpgradeUnderweight ➝ Equal$21.00 ➝ $30.00Medium
8/29/2019Bank of AmericaLower TargetUnderperform$29.00 ➝ $18.00High
8/29/2019BarclaysLower TargetUnderweight$25.00 ➝ $18.00High
8/28/2019Credit Suisse GroupReiterated RatingNeutral$31.00 ➝ $25.00High
(Data available from 6/25/2019 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/28/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/28/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/27/2024
  • 7 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/26/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2024
  • 7 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/26/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2024

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Phibro Animal Health logo
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, industrial, environmental, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
Read More

Today's Range

Now: $17.54
Low: $17.35
High: $17.61

50 Day Range

MA: $16.74
Low: $12.44
High: $18.55

52 Week Range

Now: $17.54
Low: $9.40
High: $18.70

Volume

72,014 shs

Average Volume

143,580 shs

Market Capitalization

$710.37 million

P/E Ratio

54.81

Dividend Yield

2.72%

Beta

0.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Phibro Animal Health?

The following Wall Street research analysts have issued research reports on Phibro Animal Health in the last year: Barclays PLC, BNP Paribas, Morgan Stanley, Roth Mkm, and StockNews.com.
View the latest analyst ratings for PAHC.

What is the current price target for Phibro Animal Health?

4 Wall Street analysts have set twelve-month price targets for Phibro Animal Health in the last year. Their average twelve-month price target is $14.75, suggesting a possible downside of 15.9%. Roth Mkm has the highest price target set, predicting PAHC will reach $21.00 in the next twelve months. BNP Paribas has the lowest price target set, forecasting a price of $9.00 for Phibro Animal Health in the next year.
View the latest price targets for PAHC.

What is the current consensus analyst rating for Phibro Animal Health?

Phibro Animal Health currently has 2 sell ratings, 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for PAHC.

What other companies compete with Phibro Animal Health?

How do I contact Phibro Animal Health's investor relations team?

Phibro Animal Health's physical mailing address is GLENPOINTE CENTRE EAST 3RD FLOOR 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ, 07666. The company's listed phone number is (201) 329-7300 and its investor relations email address is [email protected]. The official website for Phibro Animal Health is www.pahc.com. Learn More about contacing Phibro Animal Health investor relations.